University of Pennsylvania - Perelman Center for Advanced Medicine - Penn Radiation Oncology
Welcome,         Profile    Billing    Logout  
 8 Trials 
8 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
O'Hara, Mark H
NCT05297903: XmAb20717 in Advanced Biliary Tract Cancers

Active, not recruiting
2
27
US
XmAb20717, ANTI-PD1 × ANTI-CTLA4 BISPECIFIC MONOCLONAL ANTIBODY
Abramson Cancer Center at Penn Medicine, Xencor, Inc.
Biliary Tract Cancer
12/26
12/26
RAMP205, NCT05669482: Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer

Recruiting
1/2
40
US
avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel, Gemzar, Abraxane
Verastem, Inc.
KRAS Activating Mutation, Metastatic Cancer, Pancreas Cancer, Neoplasms Pancreatic, Malignant Neoplasm of Pancreas
05/25
12/25
AMPLIFY-7P, NCT05726864: A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors

Active, not recruiting
1/2
158
US
ELI-002 7P
Elicio Therapeutics
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, KRAS G12D, KRAS G12R, KRAS G12V, KRAS G12A, KRAS G12C, KRAS G12S, KRAS G13D, NRAS G12D, NRAS G12R, NRAS G12V, NRAS G12C, NRAS G12S
11/26
11/26
NCT03854110: Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine

Recruiting
1
64
US
GP-2250, gemcitabine
Geistlich Pharma AG, Translational Drug Development
Pancreatic Cancer, Adult
09/24
12/24
ARC-8, NCT04104672: A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies

Recruiting
1
195
US
AB680, Zimberelimab, AB122, Nab-paclitaxel, Abraxane, Gemcitabine, Gemzar
Arcus Biosciences, Inc.
Advanced Pancreatic Cancer
05/27
05/27
REVOLUTION, NCT04787991: Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma

Active, not recruiting
1
45
US
Nivolumab (Cohort A), Opdivo, Ipilimumab (Cohort A, B and C), Yervoy, Hydroxychloroquine (HCQ) (Cohort B), Plaquenil, Nab-paclitaxel (nP) (Cohort A, B and C), Abraxane, Gemcitabine (gem) (Cohort A, B and C), Gemzar, NG350A (Cohort C)
Cancer Insight, LLC, Bristol-Myers Squibb, Cancer Research Institute, New York City, Akamis Bio
Metastatic Pancreatic Adenocarcinoma
10/24
01/25
FORTIFY, NCT05165433: Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours

Active, not recruiting
1
198
Europe, US
NG-350A plus Pembrolizumab, KEYTRUDA®
Akamis Bio, Merck Sharp & Dohme LLC
Epithelial Tumor, Metastatic Cancer
03/25
05/25
NCT05484011: A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Terminated
1
5
US
odetiglucan, Imprime, BTH-1677, Imprime PGG, CDX-1140
HiberCell, Inc., Celldex Therapeutics
Metastatic Pancreatic Adenocarcinoma
03/24
03/24

Download Options